Following Saniona’s announcement that the company is initiating its Phase 2b clinical trial for Tesomet, which is being studied as a treatment for hyperphagia in Prader-Willi syndrome, the company has launched a website to help advance testing efforts for the drug.
If you would like to participate in PWS research for Saniona’s TM006 study, this website is the perfect place to start. It provides details about Tesomet and how the drug works, along with a comprehensive description of what participants should expect if they participate in the TM006 study.
According to the website, participation in the TM006 study may last a little more than one year and includes the following parts:
Screening – Up to three weeks
Part 1 (Double-Blind) – 16 to 18 weeks
Part 2 (Optional Open-Label) – 38 weeks
Requirements to participate in the TM006 study include:
- Male or female, 13 through 65 years of age
- Diagnosed with PWS
- Have a regular caregiver
- If taking, must be on a stable dose of growth hormone, antidiabetic medications, and/or lipid-lowering medications
- Must not be taking antidepressants
To learn more about the trial journey and study, visit https://www.sanionapwsstudy.com/tm006-study.
Study Center Locations
There are three study center locations for the TM006 research study, including The Sparrow Clinical Research Institute in Lansing, Michigan, Indiana University in Indianapolis, Indiana, and Rare Disease Research, LLC in Atlanta Georgia.
Find the TM006 study center locations by clicking here or on the map below.